The introduction of biological criteria has transformed quality control from descriptive process statistics to control of fulfillment of quality requirements on the basis of normally observed biological variation of analytes (1 ) . Because drugs are xenobiotic, it is difficult to determine "biological" variation. Quality requirements remain contingent on achievable instrument performance, in the most optimistic case based on best practice criteria, or on arbitrary rules.
An article by Fraser, published in 1987 (2 ), tried to address this gap (3, 4 ) . Fraser estimated the biological variation for the drug concentration on the basis of fundamental pharmacokinetic theory, assuming a first order kinetics of elimination, rapid absorption as compared to elimination, a single compartmental system, and constant half-life and dosing regimens. For drugs with Ͼ2 doses a day and/or long half-lives, these requirements were much too stringent for instrument performance (desirable CV phenobarbital Յ1%). Even with current analytical systems, these CVs are often unrealistic and contrast with variations in consecutive drug levels observed in clinical practice. Moreover, Fraser took the range from the steady-state maximum plasma concentration to the steady-state minimum plasma concentration as biological variation. In clinical practice, however, the drug level is measured at a specific time point (e.g., trough concentrations). The pharmacological variability at this time point is probably different.
To overcome the abovementioned limitations, we chose a realistic and practice-oriented approach. For several drugs that are routinely monitored in our lab, we retrospectively checked our laboratory information system for the past 7 months (January 1, 2013, to July 31, 2013) to find patients with 2 consecutive drug level determinations. To be included, the results for both determinations had to be within the therapeutic interval reported for the drug and/or the interpretative commentary on the report had to suggest continuation of the same dose for both determinations. As for most anti-epileptic drugs, a personalized seizure-free target concentration rather than a therapeutic interval is clinically used, and we report only a cutoff for toxicity. Measured concentrations below the limit of quantification were not taken into account, and differences of Ͼ75% between 2 consecutive measurements, unlikely to be caused by biological variation, were omitted from analysis. Both determinations were made by the same method on the same instrument. Except for lamotrigine, all measurements were performed on a Cobas 8000 c702 module (Roche Diagnostics). Desirable CV, bias, and allowable total error were calculated (1 ). Within-and between-patient variability was calculated using standard protocols (5 ). Analytical variability (CVa) was determined by the monthly instrument CV on lowquality control and subtracted from the total within-person (CV I ) and between-person (CV G ) variation (total CV I/G 2 -CV 2 a ϭ CV I/G 2 ) ( Table 1) . Our approach has some shortcomings. First, this method determines not only biological intraand interindividual variability, but also includes elements of preanalytical variation (e.g., sampling 
